AlphAIAlphAI — Financial news for AI agents
investing.comSEP 142 min read$ABT

Why is Abbott Laboratories stock rising today?

Abbott Laboratories (ABT) stock rose 1.2% after settling a $385M DOJ case related to infant formula, with no liability admitted. The settlement removed a legal overhang, boosting investor sentiment ahead of earnings. ABT's intraday high was $104.44. The move contrasted with broader market declines.

Original reporting
investing.com
Published Sep 14, 2026, 4:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 4:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$ABT
Bullish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABTBullishHigh
01

Why it matters

The $385M settlement clears the legal uncertainty, allowing analysts to focus on upcoming earnings and product pipelines.

02

Market read

The settlement provides a fresh catalyst for Abbott, prompting a modest price uptick and potentially influencing healthcare sector sentiment.

03

What to watch

Potential future litigation in other product lines or regulatory scrutiny could temper the rally.

Relevance 8/10Novelty 8/10Timing: mid‑day today

Background

Abbott faced a multi‑year DOJ investigation into its infant formula business, creating a persistent negative sentiment.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott Laboratories settled a $385M DOJ False Claims Act case, lifting a legal overhang and prompting a 1.2% mid‑day share rise.

Expected impact

Shares may continue to climb modestly in the near term as the legal cloud clears.

Evidence & confidence

Hundreds of millions in settlement and immediate price reaction indicate a clear catalyst with limited downside.

Market effects

Sector

Healthcare sector may see reduced risk premium as a major player resolves litigation.

Regional

U.S. equities gain slight support from the positive Abbott news amid broader market softness.

Global

Limited to U.S. markets; no immediate global ripple beyond healthcare investors.

Counterpoint

What could challenge this read

The settlement amount, while sizable, may signal deeper compliance issues that could surface later.

Key entities

  • company
    Abbott Laboratories

    U.S. healthcare company that settled DOJ False Claims Act allegations.

  • government_agency
    U.S. Department of Justice

    Agency that pursued the False Claims Act case against Abbott.

Read at source← All news

Related articles

SEP 9
$ABTMedAI 9/10

Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?

Abbott Laboratories (ABT) received FDA approval for its TactiFlex Duo Ablation Catheter to treat atrial fibrillation. The company's shares fell 2.6% to $105.52. Abbott's Electrophysiology sales grew 13.4% YoY in Q2 2026. The FDA approval is expected to drive positive market sentiment. Abbott has a market cap of $187.45 billion and an earnings yield of 5.1%.

tradingview.com2 min
SEP 8
$ABTHighAI 9/10

Abbott receives FDA approval for AFib ablation catheter

Abbott (ABT) received FDA approval for its TactiFlex Duo Ablation Catheter, which combines pulsed field ablation and radiofrequency energy for treating atrial fibrillation. The device will be used with Abbott's cardiac mapping system and is expected to support U.S. procedures soon. The approval was based on data from the FlexPulse IDE study.

grafa.com2 min
SEP 8
$ABTMedAI 8/10

If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King

Abbott Laboratories (ABT) is highlighted as a potential safe haven in case of a stock market crash, given its status as a Dividend King with 54 consecutive years of dividend increases. The company reported Q2 sales of $12.6B, up 13% YoY, and raised its full-year EPS forecast. Abbott's dividend payout ratio is 46%, and it returned $2.1B to shareholders in Q2. Growth is expected to accelerate in 2026, driven by new products and the $21B acquisition of Exact Sciences. Analysts rate ABT as a strong

yahoo.com2 min
SEP 1
$ABTMedAI 8/10

Abbott settlement and Kendamil case add to formula industry scrutiny

Abbott Nutrition agreed to pay $670 million to resolve claims related to its preterm infant formulas, without admitting liability. The settlement includes a Missouri case where a jury awarded $495 million to a plaintiff. Abbott maintains its products are safe and supported by medical professionals. Separately, Abbott challenged competitor Kendamil's advertising claims, with NAD recommending Kendamil remove certain claims about nutritional benefits.

foodnavigator.com7 min
SEP 1
$ABTHighAI 9/10

Dual glucose-ketone tracker on the way for diabetes patients – DPA

The FDA approved Abbott Laboratories' Libre Duo 10 Day, a wearable device that continuously monitors both glucose and ketone levels. This first-of-its-kind tracker aims to prevent life-threatening emergencies like diabetic ketoacidosis (DKA) by providing real-time data. Abbott claims the device simplifies monitoring for diabetes patients, who previously had to use separate tests for ketones.

simonroughneen.com2 min